98
edits
Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
Programmed death-ligand 1 (view source)
Revision as of 15:25, 15 November 2017
, 15:25, 15 November 2017→General
| (One intermediate revision by the same user not shown) | |||
| Line 7: | Line 7: | ||
==General== | ==General== | ||
*[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | *[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | ||
**Carcinoma cell is considered "PD-L1 positive" if the cell membrane is partially or completely stained. <ref name="pmid27389313">{{Cita publicación | apellido = Scheel | nombre = AH. | coautores = M. Dietel, LC. Heukamp, K. Jöhrens, T. Kirchner, S. Reu, J. Rüschoff, HU. Schildhaus, P. Schirmacher, M. Tiemann, A. Warth | título = Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. | publicación = Mod Pathol | volume = 29 | número = 10 | páginas = 1165-72 | mes = Oct | año = 2016 | doi = 10.1038/modpathol.2016.117 | pmid = 27389313 }}</ref> | |||
*The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity. | *The plethora of companion diagnostics developed for each PD-1/ PD-L1 inhibitor has created challenges, as these assays include different IHC antibody clones, staining protocols and platforms, scoring systems, and cutoffs for defining positivity. | ||
**Nivolumab - 28-8 (Dako) | |||
**Pembrolizumab - 22C3 (Dako) | |||
**Aterolizumab - SP142 (Ventana) | |||
**Durvalumab - SP263 (Ventana) | |||
**Avelumab - 73-10 (Dako) | |||
===Background=== | ===Background=== | ||